Principal investigator: Scott Dessain, MD, PhD

Technology description

LIMR’s technology enables human B cell hybridomas to display on their cell surface the monoclonal antibody they express. In particular, it eases human hybridoma cloning for a designated antigen, thus enabling rapid product development for clinically validated targets. The CHAT has used this method to clone many types of human antibodies, most recently antibodies that neutralize poliovirus or rabies virus, or that bind the NMDA receptor in the brain and cause a potentially fatal encephalitis (brain inflammation).

Business opportunity

The immune system attacks foreign substances in the body by making a large number of antibodies, proteins that stick to specific proteins called antigens. Antibodies circulate throughout the body until they find and attach to the antigen. Monoclonal antibodies can be produced from a single B-cell clone that binds to a specific site, such as a metastasis-enabling molecule on a cancer cell. LIMR’s technology makes development of human monoclonal antibodies by biotechnology companies easier and more efficient. Human antibodies encompass greater antigenic diversity and reflect the experience of the patient, for example, in overcoming a particularly aggressive cancer (where effective cancer-fighting antibodies may be found).

Using its proprietary technologies, the LIMR CHAT seeks collaborations to clone human monoclonal antibodies for use as diagnostics and therapeutics.

The global monoclonal antibodies market was valued at US $85 billion in 2015, and is expected to reach US $138.6 billion by 2024, according to the market research firm Grand View Research. Increasing demand for personalized medicine is a key factor in the expected growth of this market.

Intellectual property position

Pending patent: PCT patent application has been submitted.

Relevant publications

Sharma R, Al-Saleem FH, Panzer J, Lee J, Puligedda RD, Felicori LF, Kattala CD, Rattelle AJ, Ippolito G, Cox RH, Lynch DR, Dessain SK. (2018) Monoclonal antibodies from a patient with anti-NMDA receptor encephalitis. Ann Clin Transl Neurol. Jul 5;5(8):935-51.

Puligedda RD, Kouiavskaia D, Al-Saleem FH, Kattala CD, Nabi U, Yaqoob H, Bhagavathula VS, Sharma R, Chumakov K, Dessain SK. (2017) Characterization of human monoclonal antibodies that neutralize multiple poliovirus serotypes. Vaccine. Oct 4;35(41):5455-62.

Levites Y, O'Nuallain B, Puligedda RD, Ondrejcak T, Adekar SP, Chen C, Cruz PE, Rosario AM, Macy S, Mably AJ, Walsh DM, Vidal R, Solomon A, Brown D, Rowan MJ, Golde TE, Dessain SK. (2015) A human monoclonal IgG that binds aβ assemblies and diverse amyloids exhibits anti-amyloid activities in vitro and in vivo. J Neurosci. Apr 22;35(16):6265-76.